Certa Therapeutics’ FT011 Granted US FDA Fast Track for the Treatment of Systemic Sclerosis
Certa Therapeutics announces that the U.S. Food and Drug Administration has granted Fast Track Designation for its investigational therapy FT011 for the treatment of systemic sclerosis, having previously granted Orphan Drug Designation.
